Breaking News
More () »


YOUR HEALTH: Breakthrough lung cancer drug is on a fast track

It's a lung cancer drug that the FDA has granted breakthrough status

PITTSBURGH — In a highly unusual move, a clinical trial for a new drug was stopped early after patients were having overwhelming success on it.

The drug, Tagrisso, shows a statistically significant and clinically meaningful benefit in adjuvant treatment of lung cancer.

It's helping people like 74-year old Linda Wernikoff, who never smoked.

But after months of a chronic cough, her doctor had unexpected and unwelcome news.

"I told her I'm a straight shooter. Tell me what you think. And she said, I do think it's cancer."

Linda was diagnosed with stage 3-A lung cancer. 

She had surgery followed by chemo but wasn't sure what else could beat back the disease. 

Dr. Timothy Burns, an oncologist and a lung cancer researcher in Pittsburgh, is following the clinical trial for the drug osimertinib, or Tagrisso.

It's designed to prevent recurrence in lung cancer patients with the Epidermal Growth Factor Receptor (EFGR) mutation.

The drug was so effective, the trial was halted early to allow all patients access to the treatment.

"Overall, you saw, in all patients, about an 80 percent reduction in your chance of your cancer coming back," said Dr. Burns.

The FDA granted accelerated review for Tagrisso.

It means a decision on its use could be expected before the Summer of 2021.

Dr. Burns called the drug "practice-changing" and prescribed osimertinib to Linda.

"It just sounded wonderful," she said.  "Especially for my particular stage."

An EGFR mutation is present in about 15% of all lung cancer cases in the United States. 

The mutations are higher in lung cancers with non-smokers.

"When this gets approved, it will really make molecular testing essential for all lung cancer patients' stage and that will have implications not only for EGFR mutant patients," said Dr. Burns.

"We're also going to identify other drivers and there are already trials underway looking at ALK, which is the most frequent, and we may look back and say, 'Well, this drug not only got approved for five to 20% of patients, but also kind of shifted the way we think about early stage disease and whether we can we target it'."  

The trial is enrolled in more than 200 centers in more than 20 countries, including the U.S., Europe, South America, Asia, and the Middle East. 

If this story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Jim Mertens at jim.mertens@wqad.com or Marjorie Bekaert Thomas at mthomas@ivanhoe.com.